Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
NBRV was delisted on the 31st of July, 2023.
25 hedge funds and large institutions have $630K invested in Nabriva Therapeutics plc Ordinary Shares Ireland in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 6 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
14% less funds holding
Funds holding: 29 → 25 (-4)
49% less capital invested
Capital invested by funds: $1.25M → $630K (-$617K)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$105K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$43.4K |
| 3 |
Jane Street
New York
|
+$17.3K |
| 4 |
VF
Virtu Financial
New York
|
+$12.5K |
| 5 |
Morgan Stanley
New York
|
+$5.65K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aisling Capital Management
New York
|
-$26.4K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$16.3K |
| 3 |
JMPWA
JP Morgan Private Wealth Advisors
San Francisco,
California
|
-$12K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$6K |
| 5 |
HF
HRT Financial
New York
|
-$4K |
NBRV Hedge Fund Activity: Q2 2022 in Review
25 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) for Q2 2022, worth a combined $630K — down 49% from $1.25M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of NBRV and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.
The largest buyer was Renaissance Technologies, adding an estimated $105K. The largest seller was Aisling Capital Management, cutting an estimated $26.4K.
- 25 institutional investors held Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) as of Q2 2022, down from 29 in Q1 2022.
- Funds reported $630K of Nabriva Therapeutics plc Ordinary Shares Ireland stock for Q2 2022, down 49% quarter-over-quarter.
- 3 funds opened new Nabriva Therapeutics plc Ordinary Shares Ireland positions in Q2 2022 and 6 closed out, a net change of -3 holders.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland buyer in Q2 2022 was Renaissance Technologies, an estimated $105K added.
- The largest Nabriva Therapeutics plc Ordinary Shares Ireland seller in Q2 2022 was Aisling Capital Management, an estimated $26.4K sold.
Based on aggregated 13F filings for Q2 2022.